Mission

Mission

Avitide is dedicated to advancing our partners’ clinical pipelines and commercial manufacturing processes with a rapid, exclusive, and enabling affinity purification platform technology.

Avitide partners benefit from:

TECHNOLOGY

TECHNOLOGY

A NEW STANDARD IN SPEED.

Avitide's industry-leading 3-month service and proprietary affinity resin discovery and development technology offers unparalleled speed, performance, and product resolution that will enable bioprocess programs to define a cost-effective affinity purification solution for any class of biopharmaceutical.

A NEW STANDARD IN PRODUCT QUALITY, YIELD, AND PURITY.

On-demand, molecule-specific affinity purification enables high yield and high purity purification processes for gene therapy vectors, vaccines, bispecific antibodies, and therapeutic proteins. Let's move beyond capture: Avitide delivers novel affinity resins that can select for product quality attributes to improve upon drug product purity, safety, and potency.

BIOPROCESS-READY AFFINITY PURIFICATION PERFORMANCE.

Avitide affinity resins are more cost-effective and scalable compared to other affinity ligand and resin manufacturing technologies. The proprietary peptide-based affinity ligands and scaffolds deliver high dynamic binding capacity and cleaning/sanitization stability. To ensure line of sight to commercial resin, affinity ligand manufacturability is assessed very early in the affinity resin discovery and development process (usually within 6 weeks) so that every affinity purification solution delivered is ready to meet the rigors of biopharmaceutical manufacturing.

Avitide-Value-Proposition

Avitide is happy to share case studies on the platform’s capabilities and discuss where we can deliver affinity purification solutions for your clinical and commercial biopharmaceutical programs, life-cycle management projects, and process analytical technology needs

PARTNERING

PARTNERING

COMMITTED TO DEVELOPING LONG-TERM AND STRATEGIC RELATIONSHIPS.

DISCOVERED IN NEW HAMPSHIRE, DELIVERED WORLDWIDE.
23
PARTNERED PROGRAMS
11
PARTNERS
TEAM

TEAM

WE HAVE A PASSIONATE TEAM THAT ENJOYS TACKLING CHALLENGING PROBLEMS.

X

    • Adimab: Head of High Throughput Manufacturing
    • Merck: 10+ Years with Merck Biologics & Vaccines Research and Bioprocess R&D
    • Merck: Senior Engineer at Merck Bioprocess R&D, Automated & High-throughput Bioprocess Technologies
    • Dartmouth College, Thayer Engineering School: Merck-Sponsored Doctoral Fellow

    Kevin Isett, PhD

    Chief
    Executive Officer
    • Dartmouth College, Thayer Engineering School: Senior Research Fellow
    • Glycan Biosciences: Co-Founder and CTO
    • GlycoFi (Acquired by Merck in 2006): Senior Chemist

    Warren Kett, PhD

    Chief
    Scientific Officer
    • Adimab: Co-Founder and CEO
    • Alector: Co-Founder and Chairman of the Board
    • Arsanis: Co-Founder and President
    • GlycoFi (Acquired by Merck in 2006): Co-Founder and CSO
    • Dartmouth College: Professor of Bioengineering and Associate Provost of the Office of Entrepreneurship and Technology Transfer
    • SV Life Sciences: Venture Partner

    Tillman Gerngross, PhD

    Chairman
    of the Board
    • 20+ years in executive life science finance operations
    • PerkinElmer
    • McGladrey & Pullen
    • University of Minnesota

    Scott Kennedy

    Chief
    Financial Officer
    • Outside GC
    • Sanofi Pasteur
    • Acambis
    • Edwards and Angell
    • Boston University School of Law

    Kimberly Cornwell


    General Counsel
    • 20+ years in developing and modeling biopharmaceutical separation technologies and manufacturing processes
    • Novo Nordisk A/S – Director Mathematical Modeling
    • GE Healthcare Life Sciences – Customer Collaboration Leader
    • Amersham Pharmacia Biotech – Polymer and Surface Chemistry

    Karol Lacki, PhD

    VP
    Technology Development
    • 20+ years in bioprocess chromatography and manufacturing experience
    • Dupont: Principal Investigator
    • EMD Chemicals Inc.: Technical Manager
    • Novasep Inc.: Engineering Manager

    Grant Espie

    Head
    Resin Manufacturing
    • 30+ years in Bioprocess Chromatography Sales and Marketing
    • EMD Millipore: Director of Business Development
    • PerSeptive: Director of Sales and Marketing

    Dan Freymeyer

    Head
    Business Development
CONTACT

CONTACT

LET US KNOW HOW WE CAN HELP.

Validation Error:

Call Us 603.965.2100

Visit Us 16 Cavendish Court, Lebanon, NH 03766

AVITIDE, INC., RECEIVES ISO 9001:2015 CERTIFICATION FOR ITS AFFINITY RESIN MANUFACTURING FACILITY

Lebanon, New Hampshire – August 22, 2017 – Avitide, Inc., the industry leader in the discovery and...

08.22.2017

AVITIDE, INC., RAISES SERIES E FINANCING FROM SANDS CAPITAL VENTURES WITH BROAD PARTICIPATION FROM EARLY INVESTORS

Lebanon, New Hampshire – June 21, 2017 – Avitide, Inc., the industry leader in the discovery, and...

06.21.2017

AVITIDE, INC., EXPANDS MANAGEMENT TEAM WITH APPOINTMENTS OF LIFE SCIENCE VETERANS

Lebanon, New Hampshire – June 8, 2017 – Avitide, Inc., the industry leader in the discovery, development...

06.08.2017

Customisable Chromatography Resin Maker Avitide Boosted by Series D Funding

Visit the original article by Dan Stanton at BioPharma – Reporter. Two months on from signing a...

09.14.2016

Finding New Formats for Good Old Protein A

Visit the original article by Meghaan M. Ferreira, Ph.D. at GEN. Protein A Is Adapting To New...

06.01.2016

Bespoke Bioprocessing Resins

Full article by Randi Hernandez can be read at BioPharm International.

12.01.2015